The FDA’s controversial new drug approval program is raising serious alarms—and it’s not just about speed. What happens when the race to approve drugs outpaces the science and ethics behind them? This is the question haunting the Food and Drug Administration as Commissioner Marty Makary pushes forward with a program that promises to greenlight certain medications in as little as one month. But here’s where it gets controversial: this expedited process, favored by the Trump administration, is bypassing long-standing legal, ethical, and scientific standards that have traditionally ensured the safety and effectiveness of new medicines.
Imagine a drug approved in a fraction of the time it usually takes—sounds efficient, right? But at what cost? According to seven current or former FDA staffers who spoke anonymously to The Associated Press, the program is causing confusion and anxiety among employees already reeling from layoffs, buyouts, and leadership shake-ups. And this is the part most people miss: the program’s legal authority remains unclear. Who exactly has the power to sign off on these drugs? Traditionally, it’s been the FDA’s review scientists and their supervisors, not political appointees or senior leaders. Yet, under this new initiative, that line is blurring—and fast.
Drug reviewers are in the dark about how the program operates, and some have even been instructed to skip critical regulatory steps to meet aggressive deadlines. For instance, staffers working on a highly anticipated anti-obesity pill were told to bypass certain procedures, raising concerns about whether these drugs are being thoroughly vetted. Outside experts, like Dr. Aaron Kesselheim of Harvard Medical School, are sounding the alarm: “The concept of doing a review in one to two months just does not have scientific precedent. The FDA cannot conduct the same detailed review in such a short time—it’s simply not possible with the resources they have.”
But here’s the kicker: Despite these warnings, the program remains popular at the White House. Why? Because it’s tied to pricing concessions from drugmakers, who are rewarded with FDA vouchers for agreeing to lower their prices. For example, when Eli Lilly and Novo Nordisk announced price cuts on their obesity drugs, FDA staffers were rushed to vet new vouchers in time for President Trump’s news conference. This has sparked widespread concern that drug approvals—once grounded in objective standards—are now vulnerable to political interference.
Paul Kim, a former FDA attorney, puts it bluntly: “It’s extraordinary to have such an opaque application process, one that is obviously susceptible to politicization.” And it’s not just critics raising red flags. Even top FDA officials, like former drug director Dr. George Tidmarsh, have refused to sign off on approvals under this program due to legal concerns. Tidmarsh resigned in November following an unrelated lawsuit, but his stance underscores the unease within the agency.
Here’s where it gets even more complicated: The program isn’t codified in federal rules and regulations. Instead, details are mostly confined to an FDA website, and drugmakers apply by submitting a 350-word “statement of interest.” This lack of formal structure has created confusion, with agency leaders like Dr. Vinay Prasad directly contacting drugmakers about awarding vouchers. This raises questions about transparency and fairness—how can a program operate effectively without clear guidelines?
And this is the part that should concern everyone: Skipping review steps isn’t just a procedural issue; it’s a risk to public health. If safety problems emerge later, both the FDA and its staffers could face investigations or lawsuits. Traditionally, approvals are made by drug office directors in consultation with reviewers. Under this program, however, approvals are decided by a committee of senior leaders, with staff reviewers having no say. Kesselheim calls this “a complete reversal from the normal review process,” which is typically led by scientists immersed in the data.
Not everyone is critical. Dan Troy, the FDA’s top lawyer under President George W. Bush, argues that federal law gives the commissioner broad discretion to reorganize drug reviews. Yet, he admits the program’s lack of codification means it could be short-lived. “If you live by the press release, then you die by the press release,” Troy warns. “The next administration could wipe it out in an instant.”
So, what’s the bottom line? The program has already expanded beyond its initial scope, awarding 18 vouchers with more under consideration. This puts immense pressure on the FDA’s drug center, which has seen 20% of its staff leave in the past year. As the agency scrambles to keep up, the question remains: Are we sacrificing safety and science for speed and politics?
What do you think? Is this program a necessary innovation or a dangerous gamble? Let us know in the comments—this is a conversation that needs your voice.
